Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Employees

900

Sector

Pharmaceuticals

Calendar

Mar. 09 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-12	11.41 $	-2.65%	568,158
25-12-11	11.72 $	+1.38%	651,324
25-12-10	11.56 $	-0.52%	1,285,023
25-12-09	11.62 $	-2.11%	495,228
25-12-08	11.87 $	-0.25%	1,341,889

Delayed Quote Nyse, December 12, 2025 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.41USD

Average target price

13.50USD

Spread / Average Target

+18.32%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 04:00:02 2025-12-12 pm EST			5-day change	1st Jan Change
11.41 ^USD	-2.65%		-4.12%	+19.35%

Dec. 12	Emergent Biosolutions Receives U.S. FDA Approval for Drug Product Manufacturing of Raxibacumab At Its Winnipeg, Canada Site	CI
Dec. 12	Emergent BioSolutions Says FDA Approved SBLA to Add Winnipeg Site for Raxibacumab Work	MT

Capitalization	599M 511M 477M 449M 826M 54.28B 902M 5.57B 2.16B 25.58B 2.25B 2.2B 93.34B	P/E ratio 2025 *	7.07x	P/E ratio 2026 *	2.84x
Enterprise value	599M 511M 477M 449M 826M 54.28B 902M 5.57B 2.16B 25.58B 2.25B 2.2B 93.34B	EV / Sales 2025 *	0.74x	EV / Sales 2026 *	0.52x
Free-Float	88.74%	Yield 2025 *	-	Yield 2026 *	-

Dec. 12	Emergent Biosolutions Receives U.S. FDA Approval for Drug Product Manufacturing of Raxibacumab At Its Winnipeg, Canada Site	CI
Dec. 12	Emergent BioSolutions Says FDA Approved SBLA to Add Winnipeg Site for Raxibacumab Work	MT
Nov. 18	Emergent BioSolutions marks 10-year anniversary of the U.S. FDA approval of Narcan nasal spray and reinforces its commitment to increasing naloxone access	RE
Nov. 12	Emergent BioSolutions Inc. Announces Retirement of Louis W. Sullivan from Board of Directors, Effective November 14, 2025	CI
Nov. 27	Emergent BioSolutions Inc., Q3 2025 Earnings Call, Oct 29, 2025
Oct. 29	Emergent BioSolutions Q3 revenue beats guidance, raises full-year outlook	RE
Oct. 29	Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on May 7, 2025.	CI
Oct. 29	Emergent BioSolutions Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Oct. 29	Emergent BioSolutions Inc. Updates Earnings Guidance for the Full Year 2025	CI
Oct. 16	Emergent Biosolutions Insider Sold Shares Worth $306,080, According to a Recent SEC Filing	MT
Sep. 19	Emergent BioSolutions Inc. Secures $29 Million in MCM Product Orders from International Government Partner	CI
Sep. 19	Emergent BioSolutions secures $29 million in MCM product orders from international government partner	RE
Sep. 19	Emergent BioSolutions Secures $29 Million in Orders From International Government Partner	MT

Dec. 30	Emergent BioSolutions Shares Rise After HC Wainwright Begins Coverage With Buy Rating	MT
Dec. 30	HC Wainwright Initiates Emergent BioSolutions at Buy With $15 Price Target	MT
24-06-20	Benchmark Adjusts Emergent Biosolutions Price Target to $8 From $5, Maintains Buy Rating	MT
24-03-07	Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $5	MT
23-08-29	Benchmark Downngrades Emergent Biosolutions to Hold From Buy	MT

Emergent BioSolutions Inc. Stock

Equities

EBS

US29089Q1058

Pharmaceuticals

Valuation: Emergent BioSolutions Inc.

Chart: Emergent BioSolutions Inc.

Latest news: Emergent BioSolutions Inc.

Last Transcript: Emergent BioSolutions Inc.

Analysts' recommendations: Emergent BioSolutions Inc.

Press Releases: Emergent BioSolutions Inc.

News in other languages: Emergent BioSolutions Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Emergent BioSolutions Inc.

ETFs: Emergent BioSolutions Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Dec. 12	Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site	GL
Nov. 19	Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access	AQ
Nov. 18	Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access	GL
Nov. 18	Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access	AQ
Nov. 12	Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors	GL

24-08-20	Borsa di Italia: Wall Street sogna nuovi record
24-08-20	EN DIRECTO DESDE LOS MERCADOS: ArcelorMittal, Bankinter, CaixaBank, Prosegur Cash, IAG, Repsol, GSK, Palo Alto, GM, Kroger, GoPro...
24-08-20	Bolsa de Madrid: Wall Street sueña con nuevos récords
24-08-20	En Direct des Marchés : Bouygues, Stellantis, Voltalia, GSK, Palo Alto, GM, Kroger, GoPro...
24-08-20	Wall Street rêve à nouveau de records

1 day	-2.65%
1 week	-4.12%
Current month	+2.15%
1 month	+12.86%
3 months	+40.17%
6 months	+82.56%
Current year	+19.35%

1 week	11.16	11.99
1 month	9.02	12.28
Current year	4.02	13.41
1 year	4.02	13.41
3 years	1.42	16.66
5 years	1.42	127.2
10 years	1.42	137.61

Manager	Title	Age	Since
Joseph Papa CEO	Chief Executive Officer	69	2024-02-20
Richard Lindahl DFI	Director of Finance/CFO	71	2018-03-25
Simon Lowry CTO	Chief Tech/Sci/R&D Officer	52	2024-11-17

Director	Title	Age	Since
Zsolt Pál Harsányi CHM	Chairman	81	2022-03-31
Ronald Richard BRD	Director/Board Member	69	2004-12-31
Kathryn Zoon BRD	Director/Board Member	76	2016-09-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
EMERGENT BIOSOLUTIONS INC.	-2.65%	-4.12%	+34.55%	-4.20%	599M
ELI LILLY AND COMPANY	+1.80%	+1.70%	+30.21%	+182.67%	920B
JOHNSON & JOHNSON	+0.75%	+4.78%	+44.31%	+17.70%	510B
ABBVIE INC.	-0.29%	-1.22%	+28.81%	+35.46%	395B
ROCHE HOLDING AG	+0.96%	+0.91%	+25.09%	+6.00%	340B
ASTRAZENECA PLC	+0.33%	-0.49%	+28.39%	+18.94%	278B
NOVARTIS AG	+0.89%	-0.08%	+21.09%	+25.93%	254B
MERCK & CO., INC.	+1.30%	+0.58%	-1.67%	-10.09%	249B
NOVO NORDISK A/S	-0.90%	+6.81%	-58.92%	-31.49%	224B
AMGEN INC.	+0.11%	-3.68%	+17.41%	+17.19%	171B
Average	-0.02%	+0.11%	+16.93%	+25.81%	334.26B
Weighted average by Cap.	+0.41%	+1.15%	+21.82%	+59.34%

	2025 *	2026 *
Net sales	809M 690M 644M 606M 1.12B 73.31B 1.22B 7.52B 2.92B 34.56B 3.04B 2.97B 126B	1.16B 984M 919M 865M 1.59B 105B 1.74B 10.73B 4.16B 49.31B 4.33B 4.24B 180B
Net income	90.08M 76.73M 71.68M 67.44M 124M 8.16B 136M 837M 325M 3.85B 338M 331M 14.03B	219M 187M 174M 164M 302M 19.86B 330M 2.04B 790M 9.36B 823M 805M 34.16B
Net Debt	-	-